Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 62.66
ACOR's Cash to Debt is ranked higher than
73% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ACOR: 62.66 )
ACOR' s 10-Year Cash to Debt Range
Min: 1.11   Max: 62.66
Current: 62.66

1.11
62.66
Equity to Asset 0.73
ACOR's Equity to Asset is ranked higher than
77% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ACOR: 0.73 )
ACOR' s 10-Year Equity to Asset Range
Min: -3.44   Max: 0.74
Current: 0.73

-3.44
0.74
Interest Coverage 13.99
ACOR's Interest Coverage is ranked higher than
52% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 13.99 )
ACOR' s 10-Year Interest Coverage Range
Min: 9.82   Max: 13.99
Current: 13.99

9.82
13.99
F-Score: 5
Z-Score: 5.83
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.03
ACOR's Operating margin (%) is ranked higher than
85% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ACOR: 9.03 )
ACOR' s 10-Year Operating margin (%) Range
Min: -9345.93   Max: 12
Current: 9.03

-9345.93
12
Net-margin (%) 4.89
ACOR's Net-margin (%) is ranked higher than
84% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ACOR: 4.89 )
ACOR' s 10-Year Net-margin (%) Range
Min: -9340.5   Max: 50.67
Current: 4.89

-9340.5
50.67
ROE (%) 3.73
ACOR's ROE (%) is ranked higher than
84% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ACOR: 3.73 )
ACOR' s 10-Year ROE (%) Range
Min: -128.66   Max: 40.15
Current: 3.73

-128.66
40.15
ROA (%) 2.71
ACOR's ROA (%) is ranked higher than
85% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ACOR: 2.71 )
ACOR' s 10-Year ROA (%) Range
Min: -144.41   Max: 27.41
Current: 2.71

-144.41
27.41
ROC (Joel Greenblatt) (%) 183.75
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ACOR: 183.75 )
ACOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4297.04   Max: 908.61
Current: 183.75

-4297.04
908.61
Revenue Growth (%) 17.50
ACOR's Revenue Growth (%) is ranked higher than
89% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ACOR: 17.50 )
ACOR' s 10-Year Revenue Growth (%) Range
Min: -61.8   Max: 136.8
Current: 17.5

-61.8
136.8
» ACOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ACOR Guru Trades in Q1 2013

Jim Simons 251,300 sh (-13.14%)
Steven Cohen 100,000 sh (-86.73%)
» More
Q2 2013

ACOR Guru Trades in Q2 2013

Paul Tudor Jones 7,400 sh (New)
Steven Cohen 256,488 sh (+156.49%)
Jim Simons Sold Out
» More
Q3 2013

ACOR Guru Trades in Q3 2013

Paul Tudor Jones 7,700 sh (+4.05%)
Steven Cohen 84,913 sh (-66.89%)
» More
Q4 2013

ACOR Guru Trades in Q4 2013

Jim Simons 250,400 sh (New)
David Dreman 1,025 sh (New)
Paul Tudor Jones 17,000 sh (+120.78%)
Steven Cohen 44,981 sh (-47.03%)
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Dreman 2013-12-31 New Buy$28.89 - $36.54 $ 35.258%1025
Joel Greenblatt 2012-12-31 Sold Out 0.02%$22.48 - $26.93 $ 35.2543%0
Joel Greenblatt 2012-06-30 New Buy0.02%$21.61 - $27.02 $ 35.2548%9329
John Burbank 2012-03-31 Sold Out 0.21%$24.85 - $27.49 $ 35.2545%0
Mario Gabelli 2011-03-31 Sold Out $20.6 - $30.98 $ 35.2549%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 91.10
ACOR's P/E(ttm) is ranked lower than
63% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. ACOR: 91.10 )
ACOR' s 10-Year P/E(ttm) Range
Min: 6.35   Max: 161.37
Current: 91.1

6.35
161.37
P/B 3.50
ACOR's P/B is ranked higher than
73% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ACOR: 3.50 )
ACOR' s 10-Year P/B Range
Min: 2.5   Max: 44.88
Current: 3.5

2.5
44.88
P/S 4.30
ACOR's P/S is ranked higher than
76% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ACOR: 4.30 )
ACOR' s 10-Year P/S Range
Min: 0.12   Max: 24.53
Current: 4.3

0.12
24.53
PFCF 46.30
ACOR's PFCF is ranked lower than
55% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. ACOR: 46.30 )
ACOR' s 10-Year PFCF Range
Min: 10.97   Max: 130.85
Current: 46.3

10.97
130.85
EV-to-EBIT 37.00
ACOR's EV-to-EBIT is ranked lower than
67% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ACOR: 37.00 )
ACOR' s 10-Year EV-to-EBIT Range
Min: 13   Max: 93.5
Current: 37

13
93.5
PEG 0.30
ACOR's PEG is ranked higher than
93% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ACOR: 0.30 )
ACOR' s 10-Year PEG Range
Min: 0.22   Max: 4.87
Current: 0.3

0.22
4.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.60
ACOR's Price/Net Cash is ranked lower than
57% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. ACOR: 13.60 )
ACOR' s 10-Year Price/Net Cash Range
Min: 4.51   Max: 21.46
Current: 13.6

4.51
21.46
Price/Net Current Asset Value 10.20
ACOR's Price/Net Current Asset Value is ranked higher than
51% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ACOR: 10.20 )
ACOR' s 10-Year Price/Net Current Asset Value Range
Min: 4.34   Max: 16.39
Current: 10.2

4.34
16.39
Price/Tangible Book 3.40
ACOR's Price/Tangible Book is ranked higher than
76% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ACOR: 3.40 )
ACOR' s 10-Year Price/Tangible Book Range
Min: 2.63   Max: 42.81
Current: 3.4

2.63
42.81
Price/DCF (Projected) 2.70
ACOR's Price/DCF (Projected) is ranked higher than
62% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ACOR: 2.70 )
ACOR' s 10-Year Price/DCF (Projected) Range
Min: 2.21   Max: 22.28
Current: 2.7

2.21
22.28
Price/Median PS Value 0.80
ACOR's Price/Median PS Value is ranked higher than
82% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ACOR: 0.80 )
ACOR' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 3.17
Current: 0.8

0.58
3.17
Price/Graham Number 3.70
ACOR's Price/Graham Number is ranked lower than
52% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ACOR: 3.70 )
ACOR' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 3.05
Current: 3.7

0.86
3.05
Earnings Yield (Greenblatt) 2.70
ACOR's Earnings Yield (Greenblatt) is ranked lower than
54% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ACOR: 2.70 )
ACOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 7.7
Current: 2.7

1.1
7.7
Forward Rate of Return (Yacktman) 0.52
ACOR's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ACOR: 0.52 )
ACOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -93.5   Max: 0.7
Current: 0.52

-93.5
0.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CDG.Germany
Acorda Therapeutics, Inc. was incorporated in 1995 as a Delaware corporation. It is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The Company is managed and operated as one business. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec, under a license and collaboration agreement that it entered into in June 2009. It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. On February 6, 2012, it launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules, under its agreement with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc., following the launch by Apotex, Inc. of its generic tizanidine hydrochloride capsules. It is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide